Leica Biosystems agreed to acquire Statlab Medical Products in a deal intended to broaden Danaher’s diagnostics and anatomical pathology footprint. While financial terms were not disclosed, RBC Capital Markets analyst Dan Leonard estimated the transaction could exceed $1 billion. The acquisition is expected to expand Leica’s range of consumables and instruments for pathology workflows. For lab equipment and reagents suppliers, the move signals continued consolidation as integrated pathology platforms compete for instrument install base and recurring reagent demand.